Latest Breaking News On - Deborah geraghty - Page 1 : comparemela.com

Anokion SA: Anokion Announces New Clinical Data from the Phase 1b/2 ACeD-it Trial Supporting KAN-101 as a Potential Disease-Modifying Treatment for Celiac Disease

Two Global Phase 2 Clinical Trials, the Phase 2 portion of ACeD-it and Phase 2a SynCeD Studies, are Ongoing in Individuals with Celiac Disease New Data Presented During Digestive Disease Week® 2024

Chris brinzeyDeborah geraghtyTwo global phaseSynced studiesData presented during digestive disease weekPotential treatmentImmune toleranceHigher dose levelsNovel immune tolerance therapyCeliac diseaseDigestive disease weekFast track designationIhr portfolio

Can autoimmune diseases be cured? Scientists see hope at last

After decades of frustration and failed attempts, scientists might finally be on the cusp of developing therapies to restore immune ‘tolerance’ in conditions such as diabetes, lupus and multiple sclerosis. After decades of frustration and failed attempts, scientists might finally be on the cusp of developing therapies to restore immune ‘tolerance’ in conditions such as diabetes, lupus and multiple sclerosis.

United statesNew yorkSouth san franciscoStanford universityUniversity of chicagoUnited kingdomJeffrey hubbellAimee payneSonoma biotherapeuticsLawrence steinmanDeborah geraghtyY yangp santamariaMaximilian konigPere santamariaColumbia university vagelos college of physiciansJohns hopkins university in baltimore

Anokion SA: Anokion to Participate in BofA Healthcare Trailblazers Conference

Anokion SA: Anokion to Participate in BofA Healthcare Trailblazers Conference
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesDeborah geraghtyCara mayfieldIndiens wirtschaftIhre chancenCompany conference onStrategic communicationsDer indienDie highlights

Anokion to Participate in BofA Healthcare Trailblazers Conference

CAMBRIDGE, Mass. & LAUSANNE, Switzerland, October 19, 2023 Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced today that Deborah Geraghty, Ph.D., president and chief executive officer, will participate in the BofA Healthcare Trailblazers Private Company Conference on Thursday, October 26, 2023, in Boston, Mass.

United statesUnited kingdomDeborah geraghtyCompany conference onImmune toleranceAutoimmune diseaseBiotechnology companyDeborah geraghtyBusiness wireCeliac disease

Patient enrollment in Phase 1 RRMS trial of ANK-700 complete | Multiple Sclerosis News Today

Patient enrollment in Phase 1 RRMS trial of ANK-700 complete | Multiple Sclerosis News Today
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

Deborah geraghty